Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer

PURPOSE: Trastuzumab (TZM) improves survival and the risk of recurrence among patients with early-stage HER2+ breast cancer (BC). TZM treatment can be given intravenously (IV-TZM) or subcutaneously (SC-TZM). Although both methods have similar efficacy and safety, they differ in dosage and administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Luis, Muñiz, Sabrina, Medina, Lidia, Peña, Jose, Acevedo, Francisco, Pinto, Mauricio P., Sanchez, Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001963/
https://www.ncbi.nlm.nih.gov/pubmed/32023267
http://dx.doi.org/10.1371/journal.pone.0227961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001963/
https://www.ncbi.nlm.nih.gov/pubmed/32023267
http://dx.doi.org/10.1371/journal.pone.0227961

Ejemplares similares